Losartan reduces cardiomyocyte apoptosis in rats with heart failure
- VernacularTitle:氯沙坦降低心力衰竭大鼠心肌细胞凋亡
- Author:
Hong QIU
;
Hongfeng ZHU
- Publication Type:Journal Article
- Keywords:
heart failure;
angiotensin Ⅱ;
apoptosis;
BAX;
BCL-2
- From:
Basic & Clinical Medicine
2009;29(11):1207-1210
- CountryChina
- Language:Chinese
-
Abstract:
Objective To find the inpact(s) of Losartan on myocardial apoptosis in rats with heart failure. Methods Eight-week-old male SD rats were divided into control group (group C) , heart failure (group HF) and treatment group (group LS). Use of doxorubicin injection model, group LS at the same time in a row to the oral losartan, myocardial ultrastructure was examined by TEM. DNA-situ terminal labeling (TUNEL method) was used to detect myocardial apoptosis and myocardial BAX, BCL-2 protein expression was detected by immunohistochemistry. Results Group HF showed significant myocardial cell injury, and apoptotic bodies were found, serum CPK, CK-MB and LDH were increased. In LS group, myocardial apoptosis index was lower (P <0. 01) , myocardial cells BCL-2 expression, BAX expression reduced as compared with those in HF group. Conclusion Losartan can effectively inhibit the process of heart failure occurred in cardiomyocyte apoptosis, reverse myocardial damage and improve the prognosis of heart failure.
